Past SCAI SHOCK chair discusses no-implant shunt, clopidogrel after PCI
Click Here to Manage Email Alerts
ATLANTA — In this Healio exclusive, the past Chair of SCAI SHOCK provided a video commentary on two trials presented at the Society for Cardiovascular Angiography and Interventions Scientific Sessions.
Srihari S. Naidu, MD, FACC, FAHA, FSCAI, director of the cath lab at Westchester Medical Center and Professor of medicine at New York Medical College, reviewed the findings of a trial that assessed the potential benefits of a no-implant interatrial shut to improve HF symptoms in patients with HF with reduced or preserved ejection fraction.
As Healio previously reported, a no-implant interatrial shunt created using a 7 mm radiofrequency excision improved HF symptoms including exercise capacity, quality of life and NYHA class at 3 and 6 months, and left no hardware behind in the heart.
Naidu also discussed a second trial, which evaluated use of the P2Y12 inhibitor clopidogrel compared with aspirin monotherapy following 1 year of event-free dual antiplatelet therapy after PCI.
Researchers observed that at 30 months post-PCI, clopidogrel monotherapy was associated with nearly half the risk for all-cause death, MI, definite/probable stent thrombosis, stroke or Bleeding Academic Research Consortium type 2, 3 or 5 bleeding compared with aspirin monotherapy.
Watch the video for more.
Reference:
- Barker CM, et al. Featured Clinical Research: Part 2. Presented at: Society for Cardiovascular Angiography and Interventions Scientific Sessions; May 19-22, 2022; Atlanta.
- Wang HY, et al. Featured Clinical Research: Part 2. Presented at: Society for Cardiovascular Angiography and Interventions Scientific Sessions; May 19-22, 2022; Atlanta.
Collapse
Read more about
Click Here to Manage Email Alerts